Study of Maternal and Fetal Cardiovascular Function in Hypertensive States of Pregnancy

The pharmacological treatment strategy is then tailored to the underlying hemodynamic phenotype of each patient. That is, rather than applying a one-size-fits-all treatment for all patients, therapy is tailored to the specific characteristics of how the cardiovascular system functions in each patient (e.g., whether the problem is more related to blood volume, vascular resistance, cardiac output, etc.). The goal is to personalize therapy to more effectively treat hypertensive states of pregnancy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Preeclampsia Female Urogenital Diseases and Pregnancy Complications Hypertension, Pregnancy-Induced Pre-Eclampsia Pregnancy Complications Urogenital Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

HCUVA

El Palmar, Murcia, 30120, Spain

Location status: Recruiting

Location contact

Catalina de Paco Matallana, MD

CONTACT

[email protected]

968369500

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age greater than or equal to 18 years
Women with singleton and twin pregnancies complicated by hypertensive states of pregnancy.

Exclusion criteria

Minors under 18 years of age.
Women with mental disabilities.
Major congenital fetal anomaly.

Treatment and study plan

Primary outcomes

Prolongation of at least one week of gestation in pregnancy complicated by hypertensive state of pregnancy with antihypertensive therapy guided by hemodynamic phenotypes

Time frame: Up to 40 weeks

Number of weeks of pregnancy

Study contacts

Contact information is provided by the study sponsor or research team.

Catalina de Paco Matallana, MD

CONTACT

[email protected]

968369500

Sponsors and collaborators

Lead sponsor

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

Other

Registry information

Acronym: CARDIAC-OAT

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Mar 5, 2025
Registry last updated: Mar 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting